A single intravenous injection of eVLPs carrying a base editor targeting proprotein convertase subtilisin/kexin type 9 (Pcsk9) can achieve base editing in multiple tissues, reduce serum PCSK9 levels by 78%, and partially restore visual function when designed for retinal editing in a mouse model of blindness [126]. The gene discussed is PCSK9; the disease is Blindness.